Cargando…
A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix™ in healthy adults
Over recent decades, the global incidence of hepatitis A virus infection has been reduced by improvements in sanitation infrastructure and through immunization programs. The immunogenicity and field efficacy of the inactivated hepatitis A vaccine (Havrix™, GSK, Belgium) has been demonstrated in clin...
Autores principales: | Van Der Meeren, Olivier, Crasta, Priya, de Ridder, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514304/ https://www.ncbi.nlm.nih.gov/pubmed/26029816 http://dx.doi.org/10.1080/21645515.2015.1045167 |
Ejemplares similares
-
Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis
por: Van Der Meeren, Olivier, et al.
Publicado: (2015) -
The Immunogenicity of a Single Dose of Hepatitis A Virus Vaccines (Havrix® and Epaxal®) in Korean Young Adults
por: Lim, Jiseun, et al.
Publicado: (2014) -
Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction
por: Wang, Yongji, et al.
Publicado: (2020) -
Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction
por: Wang, Xiaoli, et al.
Publicado: (2023) -
Lasting immune memory against hepatitis B in 12–13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy
por: Behre, Ulrich, et al.
Publicado: (2016)